Shire has withdrawn its EU marketing application for its ADHDtransdermal patch product, Daytrana (methylphenidate transdermal system) for use in children, licensed from Noven. There are no plans to resubmit the filing.
"Although we are disappointed with Shire's decision not to pursue European approval, our 2009 financial guidance did not include any revenues or other financial contribution from European sales of Daytrana,"...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?